Insurance AI Agent Cost Observability Build vs Buy | Moring
Building cost observability in-house gives insurers control over attribution and data residency but competes for engineering time against the claims and underwriting roadmap; buying brings regulator-aligned monitoring quickly. The balanced path extends existing model governance structures, buys where the market is mature, and builds only the insurance-specific attribution layer.
Short answer
Building cost observability in-house gives insurers control over attribution and data residency but competes for engineering time against the claims and underwriting roadmap; buying brings regulator-aligned monitoring quickly. The balanced path extends existing model governance structures, buys where the market is mature, and builds only the insurance-specific attribution layer.
How it works
The build-versus-buy decision for cost observability should start from what insurers already have. Actuarial pricing agents extend into a domain already governed by model risk management practices that predate generative AI, which means many insurers can extend existing model governance frameworks to new AI agents rather than building parallel structures from scratch. Attribution, review, and evidence discipline exist in the organization; the question is whether the agent cost layer plugs into them or duplicates them. Building a parallel structure is the most expensive option of the three, and it is chosen more often by accident than by decision.
The build case rests on specificity. Generic cost dashboards meter tokens, while an insurer needs attribution by claim, submission, and workflow, launch costs separated from operating costs, and cost per completed case as the headline metric. Those are insurance-shaped requirements that no off-the-shelf dashboard fully anticipates, and building the attribution layer inside the insurer's own gateway and tag taxonomy keeps the data residency and reconciliation story entirely internal. Building also avoids dependence on a vendor's pricing model for the observability layer itself, which matters when observability vendors meter by ingested volume and the bill scales with how much an agent thinks.
The buy case rests on maturity and speed. Observability platforms built for regulated insurance deliver continuous monitoring, fairness auditing, and reporting aligned to regulatory expectations, reducing engineering and audit preparation overhead, and they bring dashboards, anomaly detection, and evidence export that would take quarters to reproduce. Enterprise governance guidance converges on the same prerequisite regardless of build or buy: ownership, consumption tracking, human approval, failure detection, and cost governance must exist before agent usage scales, otherwise agent usage becomes another hidden cost line buried between IT, finance, and the business teams using it. Buying accelerates reaching that baseline; building postpones it.
Either path fails without governance patterns designed into the build. Auditors respond to evidence rather than enthusiasm, and the patterns that survive examination are scoped identities, allow-listed tool access, decision logs, and complete documentation before go-live, with time to production measured in weeks of build plus acceptance testing. A bought platform that no one configured to the insurer's policies produces vendor screenshots, not compliance; a built system without review gates produces dashboards nobody defends. The governance design is the durable part, and the tooling is substitutable.
Independent verification belongs in the decision regardless. Vendor and analyst survey data is directional at best, and insurers should distinguish it clearly from findings originating with regulators or standards bodies when presenting a governance case internally, and verify vendor-supplied tooling claims against actual regulatory examination requirements before adoption. A pilot on one real workflow, a claims triage agent or an underwriting intake assistant, produces the comparison data: what the candidate layer attributes, what it costs to run, and whether its records would satisfy the insurer's own examiners.
The pragmatic resolution for most insurers is hybrid: buy the observability substrate, such as trace collection, cost metering, and dashboards, where the market is mature, and build the insurance-specific layer of attribution, per-case metrics, and NAIC- and EU AI Act-aligned evidence assembly on top. That keeps the commodity work off the internal roadmap while the differentiated controls remain in-house, which is also the configuration easiest to change later if either the market or the regulation moves.
Frequently asked questions
When does building cost observability in-house make sense for an insurer?
Building fits when the insurer needs attribution shaped by its own business, such as spend per claim, per submission, and per workflow, with launch costs separated from operating costs and data residency fully internal. Generic dashboards meter tokens rather than insurance outcomes. The approach works best when it extends existing model governance structures instead of creating parallel ones, and when engineering capacity exists alongside the claims and underwriting roadmap.
What does buying an observability platform give an insurer?
Platforms built for regulated insurance deliver continuous monitoring, fairness auditing, and reporting aligned to regulatory expectations, cutting engineering and audit preparation overhead. They arrive with dashboards, anomaly detection, and evidence export that would take quarters to reproduce internally. Buying also accelerates the baseline every option needs: ownership, consumption tracking, human approval, failure detection, and cost governance in place before agent usage scales.
What fails in both build and buy paths?
Both fail when governance is not designed into the workflow. An insurer buying a platform configured to no one's policies produces vendor screenshots rather than compliance, and a built system without review gates produces dashboards nobody defends. Auditors respond to evidence: scoped identities, allow-listed tool access, decision logs, and complete documentation before go-live. The governance patterns are the durable asset; the tooling is substitutable.
What is the pragmatic middle path?
Buy the mature substrate, including trace collection, cost metering, and dashboards, and build the insurance-specific layer on top: attribution by claim and submission, cost per completed case, and evidence assembly aligned to state regulator requests and the EU AI Act. This keeps commodity engineering off the internal roadmap, keeps differentiated controls in-house, and preserves the option to replace either layer if the market or regulation shifts.